KIRKLAND, Wash., Aug. 18 /PRNewswire/ — Cardiac Dimensions, an
early stage company focused on the development of minimally
invasive devices for the treatment of mitral valve disease and
congestive heart failure, announced today that the 12-month
follow-up results from the TITAN™ trial of the Company’s
CARILLON® Mitral Contour System will be presented at the
European Society of Cardiology 2010 Congress (ESC) on August 29,
2010 in Stockholm.
Professor Dr. Uta Hoppe of the University of Cologne, Germany,
will present the 12-month trial data and review the safety and
efficacy of the CARILLON system, a novel therapy for treating heart
failure patients suffering from functional mitral regurgitation
(FMR), a disorder of the heart’s mitral valve.
Most of the estimated 5 million people in the U.S. and more than
20 million people worldwide suffering from heart failure also
suffer from FMR, along with dilated cardiomyopathy. Unfortunately,
most of these patients have few options and are inadequately
treated using medical management. While surgical options exist and
can be effective in reducing FMR, they are infrequently used due to
the burden of the surgery itself, which can be associated with high
operative morbidity and mortality rates.
The CARILLON Mitral Contour System is a non-surgical, minimally
invasive device designed to repair the mitral valve in these
patients and reduce FMR. It combines a proprietary implantable
device and a percutaneous delivery system.
The 12-month follow-up trial results are highly anticipated
because the previously released six-month data presented at TCT
2009 was very promising, noted Professor Dr. Michael Haude of the
Stadtische Kliniken Neuss, Lukaskrankenhaus, Germany, one of the
study investigators along with Professor Dr. Hoppe.
“In my experience this device presents key advantages, such as
an easy to learn technique and immediate assessment of efficacy
coupled with peri-procedural recaptu
‘/>”/>
